Circulogene Theranostics, UAB Comprehensive Cancer Center Announce Research Agreement
BIRMINGHAM, Ala., February 10, 2016 (BUSINESS WIRE) – Circulogene Theranostics, the only biotechnology company able to enrich circulating cell-free DNA (cfDNA) from a single blood drop for patient-specific monitoring of cancer, has announced a research agreement with the University of Alabama Birmingham (UAB) Comprehensive Cancer Center.
The first clinical trial to be conducted in coordination with the UAB Comprehensive Cancer Center – one of the nation’s leading cancer research and treatment centers – will study the effectiveness of traditional tissue biopsies compared to liquid biopsies in tumor detection and monitoring.
“We’re eager to work with such a highly respected group of researchers who recognize the unique ability of our proprietary enrichment technique to provide maximal DNA data output with minimal input,” said Circulogene Theranostics CEO Mike Mullen. “We look forward to aligning with the world-renowned UAB cancer center to further evaluate the effectiveness of our droplet-volumes-of-blood technology.”
Commercially launched in November 2015, Circulogene’s cfDNA liquid biopsy products enable the fast, accurate and personalized testing of 10 tumor types, including breast, lung and colon cancer. Non-invasive liquid biopsy techniques represent a potential major advance over traditional surgical tumor biopsies, which are costly, time consuming and only sample a small portion of tumor tissue. This can result in the missing of critical tumor information, which can significantly change a patient’s treatment and prognosis.
Circulogene’s proprietary enrichment methodology, which can collect more than 100 times more cfDNA with just 1/10 of the blood compared to the current industry standard for non-invasive liquid biopsy testing, is a powerful research target. The company’s droplet-volumes-of blood methodology is capable of detecting nearly 3000 cancer mutations on 50 well-established cancer-associated genes for its 10 cancer profiles and potentially provides the most precise, rapid and cost-effective monitoring and targeted treatment of cancer possible.
Circulogene is Clinical Laboratory Improvement Amendments (CLIA) certified and currently provides testing for the following cancers: breast, colorectal, lung, gastric, gastrointestinal stromal (GIST), hematological, melanoma, ovarian, pancreatic and thyroid. For more information, visit our website, connect with us on LinkedIn, email us at email@example.com or call 855-614-7083. Clinicians interested in ordering the test may visit the Contact page on Circulogene’s website.
About Circulogene Theranostics
Headquartered in Birmingham, Ala., Circulogene Theranostics is an innovative molecular diagnostics company founded and operated by a team of experienced industry executives and skilled molecular diagnostics scientists. Applying its proprietary laboratory developed test for cfDNA liquid biopsies, Circulogene has developed the only droplet-volume, next-generation sequencing (NGS) method to provide full genomic load analysis, enabling more accurate data to help clinicians and their patients. For more information, visit www.circulogene.com or call 855-614-7083.
Armada Medical Marketing
303-623-1190 ext. 230